Zinzani,, P. L. Et Al. 2021. Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Ash Annual Meeting 2021 , (ATLANTA, United States Of America).

Zinzani,, P. L., Thieblemont, C., Melnichenko, V., Bouabdallah, K., Waleswski, J., Majlis, A., ... Fogliatto, L.(2021). Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma . Ash Annual Meeting 2021, ATLANTA, United States Of America

Zinzani,, Pier Et Al. "Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma," Ash Annual Meeting 2021, ATLANTA, United States Of America, 2021

Zinzani,, Pier L. Et Al. "Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma." Ash Annual Meeting 2021 , ATLANTA, United States Of America, 2021

Zinzani,, P. L. Et Al. (2021) . "Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma." Ash Annual Meeting 2021 , ATLANTA, United States Of America.

@conferencepaper{conferencepaper, author={Pier Luigi Zinzani, Et Al. }, title={Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma}, congress name={Ash Annual Meeting 2021}, city={ATLANTA}, country={United States Of America}, year={2021}}